Thomas, A. et al. Scientific and genomic traits of small cell lung most cancers in by no means people who smoke: outcomes from a retrospective multicenter cohort examine. Chest 158, 1723–1733 (2020).
Varghese, A. M. et al. Small-cell lung cancers in sufferers who by no means smoked cigarettes. J. Thorac. Oncol. 9, 892–896 (2014).
Wang, S. et al. Survival modifications in sufferers with small cell lung most cancers and disparities between totally different sexes, socioeconomic statuses and ages. Sci. Rep. 7, 1339 (2017).
Yang, W. et al. Variations between superior giant cell neuroendocrine carcinoma and superior small cell lung most cancers: a propensity rating matching evaluation. J. Most cancers 14, 1541–1552 (2023).
Liu, S. V. et al. Up to date total survival and PD-L1 subgroup evaluation of sufferers with extensive-stage small-cell lung most cancers handled with atezolizumab, carboplatin, and etoposide (IMpower133). J. Clin. Oncol. 39, 619–630 (2021).
Paz-Ares, L. et al. Durvalumab, with or with out tremelimumab, plus platinum-etoposide in first-line remedy of extensive-stage small-cell lung most cancers: 3-year total survival replace from CASPIAN. ESMO Open. 7, 100408 (2022).
Liu, S. V. et al. 5-year survival in sufferers with ES-SCLC handled with atezolizumab in IMpower133: imbrella a extension examine outcomes [abstract OA01.04]. J. Thorac. Oncol. 18, S44–S45 (2023).
Rudin, C. M., Brambilla, E., Faivre-Finn, C. & Sage, J. Small-cell lung most cancers. Nat. Rev. Dis. Prim. 7, 3 (2021).
Thomas, A., Pattanayak, P., Szabo, E. & Pinsky, P. Traits and outcomes of small cell lung most cancers detected by CT screening. Chest 154, 1284–1290 (2018).
Tune, P. et al. M3 muscarinic receptor antagonists inhibit small cell lung carcinoma progress and mitogen-activated protein kinase phosphorylation induced by acetylcholine secretion. Most cancers Res. 67, 3936–3944 (2007).
Friedman, J. R. et al. Acetylcholine signaling system in development of lung cancers. Pharmacol. Ther. 194, 222–254 (2019).
Soomro, Z. et al. Paraneoplastic syndromes in small cell lung most cancers. J. Thorac. Dis. 12, 6253–6263 (2020).
Roth, B. J. et al. Randomized examine of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of those two regimens in intensive small-cell lung most cancers: a part III trial of the Southeastern Most cancers Examine Group. J. Clin. Oncol. 10, 282–291 (1992).
Sundstrøm, S. et al. Cisplatin and etoposide routine is superior to cyclophosphamide, epirubicin, and vincristine routine in small-cell lung most cancers: outcomes from a randomized part III trial with 5 years’ follow-up. J. Clin. Oncol. 20, 4665–4672 (2002).
Zhang, S. & Cheng, Y. Immunotherapy for extensive-stage small-cell lung most cancers: present panorama and future views. Entrance. Oncol. 13, 1142081 (2023).
Torres-Durán, M. et al. Small-cell lung most cancers in never-smokers. ESMO Open. 6, 100059 (2021).
Moffat, G. T., Wang, T. & Robinson, A. G. Small cell lung most cancers in gentle/by no means people who smoke – a task for molecular testing? J. Natl Compr. Canc Netw. 21, 336–339 (2023).
Marcoux, N. et al. EGFR-mutant adenocarcinomas that rework to small-cell lung most cancers and different neuroendocrine carcinomas: medical outcomes. J. Clin. Oncol. 37, 278–285 (2019).
Quintanal-Villalonga, A. et al. Multi-omic evaluation of lung tumors defines pathways activated in neuroendocrine transformation. Most cancers Discov. 11, 3028–3047 (2021).
Pleasance, E. D. et al. A small-cell lung most cancers genome with complicated signatures of tobacco publicity. Nature 463, 184–190 (2010).
Yarchoan, M., Hopkins, A. & Jaffee, E. M. Tumor mutational burden and response fee to PD-1 inhibition. N. Engl. J. Med. 377, 2500–2501 (2017).
Horn, L. et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung most cancers. N. Engl. J. Med. 379, 2220–2229 (2018).
Hellmann, M. D. et al. Tumor mutational burden and efficacy of nivolumab monotherapy and together with ipilimumab in small-cell lung most cancers. Most cancers Cell 33, 853–861.e4 (2018).
Doyle, A. et al. Markedly decreased expression of sophistication I histocompatibility antigens, protein, and mRNA in human small-cell lung most cancers. J. Exp. Med. 161, 1135–1151 (1985).
George, J. et al. Complete genomic profiles of small cell lung most cancers. Nature 524, 47–53 (2015).
Meuwissen, R. et al. Induction of small cell lung most cancers by somatic inactivation of each Trp53 and Rb1 in a conditional mouse mannequin. Most cancers Cell 4, 181–189 (2003).
Febres-Aldana, C. A. et al. Rb tumor suppressor in small cell lung most cancers: mixed genomic and IHC evaluation with an outline of a definite Rb-proficient subset. Clin. Most cancers Res. 28, 4702–4713 (2022).
Sivakumar, S. et al. Integrative evaluation of a big real-world cohort of small cell lung most cancers identifies distinct genetic subtypes and insights into histologic transformation. Most cancers Discov. 13, 1572–1591 (2023).
Wagner, A. H. et al. Recurrent WNT pathway alterations are frequent in relapsed small cell lung most cancers. Nat. Commun. 9, 3787 (2018).
Sakre, N. et al. RICTOR amplification identifies a subgroup in small cell lung most cancers and predicts response to medicine concentrating on mTOR. Oncotarget 8, 5992–6002 (2017).
Schwendenwein, A. et al. Molecular profiles of small cell lung most cancers subtypes: therapeutic implications. Mol. Ther. Oncol. 20, 470–483 (2021).
Most cancers Genome Atlas Analysis Community. Complete molecular profiling of lung adenocarcinoma. Nature 511, 543–550 (2014).
Schram, A. M., Chang, M. T., Jonsson, P. & Drilon, A. Fusions in stable tumours: diagnostic methods, focused remedy, and purchased resistance. Nat. Rev. Clin. Oncol. 14, 735–748 (2017).
Iwakawa, R. et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung most cancers. Genes Chromosomes Most cancers 52, 802–816 (2013).
Rudin, C. M. et al. Complete genomic evaluation identifies SOX2 as a ceaselessly amplified gene in small-cell lung most cancers. Nat. Genet. 44, 1111–1116 (2012).
Ciampricotti, M. et al. Rlf–Mycl gene fusion drives tumorigenesis and metastasis in a mouse mannequin of small cell lung most cancers. Most cancers Discov. 11, 3214–3229 (2021).
der Hollander, J. et al. Aurora kinases A and B are up-regulated by Myc and are important for upkeep of the malignant state. Blood 116, 1498–1505 (2010).
Dominguez-Sola, D. & Gautier, J. MYC and the management of DNA replication. Chilly Spring Harb. Perspect. Med. 4, a014423 (2014).
Dauch, D. et al. A MYC–aurora kinase A protein complicated represents an actionable drug goal in p53-altered liver most cancers. Nat. Med. 22, 744–753 (2016).
Sen, T. et al. CHK1 inhibition in small-cell lung most cancers produces single-agent exercise in biomarker-defined illness subsets and mixture exercise with cisplatin or olaparib. Most cancers Res. 77, 3870–3884 (2017).
Byers, L. A. et al. A part II trial of prexasertib (LY2606368) in sufferers with extensive-stage small-cell lung most cancers. Clin. Lung Most cancers 22, 531–540 (2021).
Owonikoko, T. Okay. et al. Randomized part II examine of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line remedy for SCLC: main and correlative biomarker analyses. J. Thorac. Oncol. 15, 274–287 (2020).
Grunblatt, E. et al. MYCN drives chemoresistance in small cell lung most cancers whereas USP7 inhibition can restore chemosensitivity. Genes. Dev. 34, 1210–1226 (2020).
Liu, Y. et al. A examine on totally different therapies and prognosis-related elements for 101 sufferers with SCLC and mind metastases. Most cancers Biol. Ther. 18, 670–675 (2017).
Li, N., Chu, Y. & Tune, Q. Mind metastasis in sufferers with small cell lung most cancers. Int. J. Gen. Med. 14, 10131–10139 (2021).
Lord, C. J. & Ashworth, A. PARP inhibitors: artificial lethality within the clinic. Science 355, 1152–1158 (2017).
Sorscher, S. et al. Charge of pathogenic germline variants in sufferers with lung most cancers. JCO Summary. Oncol. 7, e2300190 (2023).
Tlemsani, C. et al. Complete-exome sequencing reveals germline-mutated small cell lung most cancers subtype with favorable response to DNA repair-targeted therapies. Sci. Transl. Med. 13, eabc7488 (2021).
Richards, S. et al. Requirements and tips for the interpretation of sequence variants: a joint consensus suggestion of the American School of Medical Genetics and Genomics and the Affiliation for Molecular Pathology. Genet. Med. 17, 405–424 (2015).
Gazdar, A. F., Carney, D. N., Nau, M. M. & Minna, J. D. Characterization of variant subclasses of cell traces derived from small cell lung most cancers having distinctive biochemical, morphological, and progress properties. Most cancers Res. 45, 2924–2930 (1985).
Rudin, C. M. et al. Molecular subtypes of small cell lung most cancers: a synthesis of human and mouse mannequin knowledge. Nat. Rev. Most cancers 19, 289–297 (2019).
Puri, S. et al. Actual-world multiomic characterization of small cell lung most cancers subtypes to disclose differential expression of clinically related biomarkers [abstract]. J. Clin. Oncol. 39 (Suppl. 15), 8508 (2021).
Qu, S. et al. Molecular subtypes of main small cell lung most cancers tumors and their associations with neuroendocrine and therapeutic markers. J. Thorac. Oncol. 17, 141–153 (2021).
Eire, A. S. et al. MYC drives temporal evolution of small cell lung most cancers subtypes by reprogramming neuroendocrine destiny. Most cancers Cell 38, 60–78.e12 (2020).
Owonikoko, T. Okay. et al. YAP1 expression in SCLC defines a definite subtype with T-cell-inflamed phenotype. J. Thorac. Oncol. 16, 464–476 (2021).
Baine, M. Okay. et al. SCLC subtypes outlined by ASCL1, NEUROD1, POU2F3, and YAP1: a complete immunohistochemical and histopathologic characterization. J. Thorac. Oncol. 15, 1823–1835 (2020).
Homosexual, C. M. et al. Patterns of transcription issue packages and immune pathway activation outline 4 main subtypes of SCLC with distinct therapeutic vulnerabilities. Most cancers Cell 39, 346–360.e7 (2021).
Simpson, Okay. L. et al. A biobank of small cell lung most cancers CDX fashions elucidates inter- and intratumoral phenotypic heterogeneity. Nat. Most cancers 1, 437–451 (2020).
Jin, Y. et al. Identification of TAZ because the important molecular change in orchestrating SCLC phenotypic transition and metastasis. Natl Sci. Rev. 9, nwab2023 (2022).
Tlemsani, C. et al. SCLC-CellMiner: a useful resource for small cell lung most cancers cell line genomics and pharmacology based mostly on genomic signatures. Cell Rep. 33, 108296 (2020).
Polley, E. et al. Small cell lung most cancers display of oncology medicine, investigational brokers, and gene and microRNA expression. J. Natl Most cancers Inst. 108, djw122 (2016).
Caeser, R. et al. MAPK pathway activation selectively inhibits ASCL1-driven small cell lung most cancers. iScience 24, 103224 (2021).
Chan, J. M. et al. Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung most cancers. Most cancers Cell 39, 1479–1496.e18 (2021).
Zhang, W. et al. Small cell lung most cancers tumors and preclinical fashions show heterogeneity of neuroendocrine phenotypes. Transl. Lung Most cancers Res. 7, 32–49 (2018).
Balanis, N. G. et al. Pan-cancer convergence to a small-cell neuroendocrine phenotype that shares susceptibilities with hematological malignancies. Most cancers Cell 36, 17–34.e17 (2019).
Wang, L. et al. A genetically outlined illness mannequin reveals that urothelial cells can provoke divergent bladder most cancers phenotypes. Proc. Natl Acad. Sci. USA 117, 563–572 (2020).
Thomas, A. et al. Therapeutic concentrating on of ATR yields sturdy regressions in small cell lung cancers with excessive replication stress. Most cancers Cell 39, 566–579.e7 (2021).
Lissa, D. et al. Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived fashions. Nat. Commun. 13, 2023 (2022).
Bebber, C. M. et al. Ferroptosis response segregates small cell lung most cancers (SCLC) neuroendocrine subtypes. Nat. Commun. 12, 2048 (2021).
Liu, S. V. et al. IMpower133: gene expression (GE) evaluation in long-term survivors (LTS) with ES-SCLC handled with first-line carboplatin and etoposide (CE) ± atezolizumab (atezo) [abstract VP5-2021]. Ann. Oncol. 32, 1063–1065 (2021).
Roper, N. et al. Notch signaling and efficacy of PD-1/PD-L1 blockade in relapsed small cell lung most cancers. Nat. Commun. 12, 3880 (2021).
Nabet, B. Y. et al. Immune heterogeneity in small-cell lung most cancers and vulnerability to immune checkpoint blockade. Most cancers Cell 42, 429–443.e4 (2024).
Saunders, L. R. et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci. Transl. Med. 7, 302ra136 (2015).
Blackhall, F. et al. Efficacy and security of rovalpituzumab tesirine in contrast with topotecan as second-line remedy in DLL3-high SCLC: outcomes from the part 3 TAHOE examine. J. Thorac. Oncol. 16, 1547–1558 (2021).
Jaspers, J. E. et al. IL-18-secreting CAR T cells concentrating on DLL3 are extremely efficient in small cell lung most cancers fashions. J. Clin. Make investments. 133, e166028 (2023).
Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T-cell engagers for most cancers immunotherapy. Immunol. Cell Biol. 93, 290–296 (2015).
Giffin, M. J. et al. AMG 757, a half-life prolonged, DLL3-targeted bispecific T-cell engager, exhibits excessive efficiency and sensitivity in preclinical fashions of small-cell lung most cancers. Clin. Most cancers Res. 27, 1526–1537 (2021).
Paz-Ares, L. et al. Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung most cancers: an open-label, part I examine. J. Clin. Oncol. 41, 2893–2903 (2023).
Ahn, M. J. et al. Tarlatamab for sufferers with beforehand handled small-cell lung most cancers. N. Engl. J. Med. 389, 2063–2075 (2023).
FDA. FDA grants accelerated approval to tarlatamab-dlle for intensive stage small cell lung most cancers. https://www.fda.gov/medicine/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer (2024).
Hipp, S. et al. A bispecific DLL3/CD3 IgG-like T-cell participating antibody induces antitumor responses in small cell lung most cancers. Clin. Most cancers Res. 26, 5258–5268 (2020).
Rudin, C. M. et al. Rising therapies concentrating on the delta-like ligand 3 (DLL3) in small cell lung most cancers. J. Hematol. Oncol. 16, 66 (2023).
Hafezi, S. & Rahmani, M. Focusing on BCL-2 in most cancers: advances, challenges, and views. Cancers 13, 1292 (2021).
Valko, Z. et al. Twin concentrating on of BCL-2 and MCL-1 within the presence of BAX breaks venetoclax resistance in human small cell lung most cancers. Br. J. Most cancers 128, 1850–1861 (2023).
Khan, S. et al. Co-targeting BCL-XL and MCL-1 with DT2216 and AZD8055 synergistically inhibit small-cell lung most cancers progress with out inflicting on-target toxicities in mice. Cell Dying Discov. 9, 1 (2023).
Paik, P. Okay. et al. A part II examine of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung most cancers. Lung Most cancers 74, 481–485 (2011).
Rudin, C. M. et al. Randomized part II examine of carboplatin and etoposide with or with out the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung most cancers: CALGB 30103. J. Clin. Oncol. 26, 870–876 (2008).
Chalishazar, M. D. et al. MYC-driven small-cell lung most cancers is metabolically distinct and susceptible to arginine depletion. Clin. Most cancers Res. 25, 5107–5121 (2019).
Han, H. et al. Small-molecule MYC inhibitors suppress tumor progress and improve immunotherapy. Most cancers Cell 36, 483–497.e15 (2019).
Demma, M. J. et al. Omomyc reveals new mechanisms to inhibit the MYC oncogene. Mol. Cell. Biol. 39, e00248-19 (2019).
Gavory, G. et al. Identification of MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD) for the remedy of cancers with Myc-induced translational habit [abstract]. Most cancers Res. 82 (Suppl. 12), 3929 (2022).
Heeke, S. et al. Tumor- and circulating-free DNA methylation identifies clinically related small cell lung most cancers subtypes. Most cancers Cell 42, 225–237.e5 (2024).
Huang, Y. H. et al. POU2F3 is a grasp regulator of a tuft cell-like variant of small cell lung most cancers. Genes. Dev. 32, 915–928 (2018).
Chiappori, A. A. et al. A randomized part II examine of linsitinib (OSI-906) versus topotecan in sufferers with relapsed small-cell lung most cancers. Oncologist 21, 1163–1164 (2016).
Belani, C. P. et al. Vismodegib or cixutumumab together with customary chemotherapy for sufferers with extensive-stage small cell lung most cancers: a trial of the ECOG-ACRIN Most cancers Analysis Group (E1508). Most cancers 122, 2371–2378 (2016).
Pietanza, M. C. et al. Randomized, double-blind, part II examine of temozolomide together with both veliparib or placebo in sufferers with relapsed-sensitive or refractory small-cell lung most cancers. J. Clin. Oncol. 36, 2386–2394 (2018).
Farago, A. F. et al. Mixture olaparib and temozolomide in relapsed small-cell lung most cancers. Most cancers Discov. 9, 1372–1387 (2019).
McColl, Okay. et al. Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung most cancers. Oncotarget 8, 73745–73756 (2017).
Horie, M., Saito, A., Ohshima, M., Suzuki, H. I. & Nagase, T. YAP and TAZ modulate cell phenotype in a subset of small cell lung most cancers. Most cancers Sci. 107, 1755–1766 (2016).
Wooten, D. J. et al. Techniques-level community modeling of small cell lung most cancers subtypes identifies grasp regulators and destabilizers. PLoS Comput. Biol. 15, e1007343 (2019).
Peifer, M. et al. Integrative genome analyses determine key somatic driver mutations of small-cell lung most cancers. Nat. Genet. 44, 1104–1110 (2012).
Whyte, W. A. et al. Grasp transcription elements and mediator set up super-enhancers at key cell identification genes. Cell 153, 307–319 (2013).
Parker, S. C. et al. Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human illness danger variants. Proc. Natl Acad. Sci. USA 110, 17921–17926 (2013).
Pozo, Okay. et al. ASCL1, NKX2-1, and PROX1 co-regulate subtype-specific genes in small-cell lung most cancers. iScience 24, 102953 (2021).
Tsherniak, A. et al. Defining a most cancers dependency map. Cell 170, 564–576.e16 (2017).
Kim, H. J., Cantor, H. & Cosmopoulos, Okay. Overcoming immune checkpoint blockade resistance through EZH2 inhibition. Traits Immunol. 41, 948–963 (2020).
Poirier, J. T. et al. DNA methylation in small cell lung most cancers defines distinct illness subtypes and correlates with excessive expression of EZH2. Oncogene 34, 5869–5878 (2015).
Kirk, N. A., Kim, Okay. B. & Park, Okay. S. Impact of chromatin modifiers on the plasticity and immunogenicity of small-cell lung most cancers. Exp. Mol. Med. 54, 2118–2127 (2022).
Mahadevan, N. R. et al. Intrinsic immunogenicity of small cell lung carcinoma revealed by its mobile plasticity. Most cancers Discov. 11, 1952–1969 (2021).
Burr, M. L. et al. An evolutionarily conserved operate of polycomb silences the MHC class I antigen presentation pathway and permits immune evasion in most cancers. Most cancers Cell 36, 385–401.e8 (2019).
Shi, Y. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).
Augert, A. et al. Focusing on NOTCH activation in small cell lung most cancers by means of LSD1 inhibition. Sci. Sign. 12, eaau2922 (2019).
Mohammad, H. P. et al. A DNA hypomethylation signature predicts antitumor exercise of LSD1 inhibitors in SCLC. Most cancers Cell 28, 57–69 (2015).
Bauer, T. M. et al. Section I, open-label, dose-escalation examine of the protection, pharmacokinetics, pharmacodynamics, and efficacy of GSK2879552 in relapsed/refractory SCLC. J. Thorac. Oncol. 14, 1828–1838 (2019).
Hiatt, J. B. et al. Inhibition of LSD1 with bomedemstat sensitizes small cell lung most cancers to immune checkpoint blockade and T-cell killing. Clin. Most cancers Res. 28, 4551–4564 (2022).
Shukla, V. et al. ASXL3 is a novel pluripotency think about human respiratory epithelial cells and a possible therapeutic goal in small cell lung most cancers. Most cancers Res. 77, 6267–6281 (2017).
Zhao, Z. et al. PAX9 determines epigenetic state transition and cell destiny in most cancers. Most cancers Res. 81, 4696–4708 (2021).
Chao, Y. L. & Pecot, C. V. Focusing on epigenetics in lung most cancers. Chilly Spring Harb. Perspect. Med. 11, a038000 (2021).
Sequist, L. V. et al. Genotypic and histological evolution of lung cancers buying resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
Ziller, M. J. et al. Charting a dynamic DNA methylation panorama of the human genome. Nature 500, 477–481 (2013).
Varley, Okay. E. et al. Dynamic DNA methylation throughout numerous human cell traces and tissues. Genome Res. 23, 555–567 (2013).
Rubin, M. A., Bristow, R. G., Thienger, P. D., Dive, C. & Imielinski, M. Influence of lineage plasticity to and from a neuroendocrine phenotype on development and response in prostate and lung cancers. Mol. Cell 80, 562–577 (2020).
Stine, Z. E., Walton, Z. E., Altman, B. J., Hsieh, A. L. & Dang, C. V. MYC, metabolism, and most cancers. Most cancers Discov. 5, 1024–1039 (2015).
Cargill, Okay. R., Hasken, W. L., Homosexual, C. M. & Byers, L. A. Various vitality: breaking down the various metabolic options of lung cancers. Entrance. Oncol. 11, 757323 (2021).
van der Lee, I. et al. Single-agent gemcitabine in sufferers with resistant small-cell lung most cancers. Ann. Oncol. 12, 557–561 (2001).
Cargill, Okay. R. et al. Focusing on MYC-enhanced glycolysis for the remedy of small cell lung most cancers. Most cancers Metab. 9, 33 (2021).
Mollaoglu, G. et al. MYC drives development of small cell lung most cancers to a variant neuroendocrine subtype with vulnerability to aurora kinase inhibition. Most cancers Cell 31, 270–285 (2017).
Pedersen, S. et al. Figuring out metabolic alterations in newly recognized small cell lung most cancers sufferers. Metab. Open. 12, 100127 (2021).
Chen, H. Z. et al. Genomic and transcriptomic characterization of relapsed SCLC by means of speedy analysis post-mortem. JTO Clin. Res. Rep. 2, 100164 (2021).
Gardner, E. E. et al. Chemosensitive relapse in small cell lung most cancers proceeds by means of an EZH2-SLFN11 axis. Most cancers Cell 31, 286–299 (2017).
Lim, J. S. et al. Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung most cancers. Nature 545, 360–364 (2017).
Abdo Hassan, W. et al. Notch1 controls cell chemoresistance in small cell lung carcinoma cells. Thorac. Most cancers 7, 123–128 (2016).
Kim, J. W., Ko, J. H. & Sage, J. DLL3 regulates Notch signaling in small cell lung most cancers. iScience 25, 105603 (2022).
Ventola, C. L. Most cancers immunotherapy, half 1: present methods and brokers. Pharm. Ther. 42, 375–383 (2017).
Iclozan, C., Antonia, S., Chiappori, A., Chen, D. T. & Gabrilovich, D. Therapeutic regulation of myeloid-derived suppressor cells and immune response to most cancers vaccine in sufferers with intensive stage small cell lung most cancers. Most cancers Immunol. Immunother. 62, 909–918 (2013).
George, J. et al. Genomic amplification of CD274 (PD-L1) in small-cell lung most cancers. Clin. Most cancers Res. 23, 1220–1226 (2017).
Hamilton, G. & Rath, B. Immunotherapy for small cell lung most cancers: mechanisms of resistance. Skilled. Opin. Biol. Ther. 19, 423–432 (2019).
Acheampong, E. et al. Tumour PD-L1 expression in small-cell lung most cancers: a scientific evaluate and meta-analysis. Cells 9, 2393 (2020).
Pavan, A. et al. Immunotherapy in small-cell lung most cancers: from molecular guarantees to medical challenges. J. Immunother. Most cancers 7, 205 (2019).
Paz-Ares, L. et al. Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small cell lung most cancers (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden. Clin. Most cancers Res. 30, 824–835 (2024).
Peters, S. et al. Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) in 1L metastatic NSCLC: outcomes by blood tumor mutational burden (bTMB) in POSEIDON [abstract]. Most cancers Res. 83 (Suppl. 8), CT080 (2023).
Rudin, C. M. et al. Exploratory biomarker evaluation of the part 3 KEYNOTE-604 examine of pembrolizumab plus etoposide for extensive-stage SCLC [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 8503 (2023).
Reck, M. et al. Ipilimumab together with paclitaxel and carboplatin as first-line remedy in extensive-disease-small-cell lung most cancers: outcomes from a randomized, double-blind, multicenter part 2 trial. Ann. Oncol. 24, 75–83 (2013).
Reck, M. et al. Section III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung most cancers. J. Clin. Oncol. 34, 3740–3748 (2016).
Paz-Ares, L. et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line remedy of extensive-stage small-cell lung most cancers (CASPIAN): a randomised, managed, open-label, part 3 trial. Lancet 394, 1929–1939 (2019).
Ott, P. A. et al. Pembrolizumab in sufferers with extensive-stage small-cell lung most cancers: outcomes from the part Ib KEYNOTE-028 examine. J. Clin. Oncol. 35, 3823–3829 (2017).
Rudin, C. M. et al. Pembrolizumab or placebo plus etoposide and platinum as first-line remedy for extensive-stage small-cell lung most cancers: randomized, double-blind, part III KEYNOTE-604 examine. J. Clin. Oncol. 38, 2369–2379 (2020).
Rudin, C. M. et al. SKYSCRAPER-02: tiragolumab together with atezolizumab plus chemotherapy in untreated extensive-stage small-cell lung most cancers. J. Clin. Oncol. 42, 324–335 (2020).
Senan, S. et al. Design and rationale for a part III, randomized, placebo-controlled trial of durvalumab with or with out tremelimumab after concurrent chemoradiotherapy for sufferers with limited-stage small-cell lung most cancers: the ADRIATIC examine. Clin. Lung Most cancers 21, e84–e88 (2020).
Spigel, D. R. et al. ADRIATIC: Durvalumab (D) as consolidation remedy (tx) for sufferers (pts) with limited-stage small-cell lung most cancers (LS-SCLC)]summary]. J. Clin. Oncol. 42 (Suppl. 17), LBA5 (2024).
Spigel, D. R. et al. 5-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung most cancers. J. Clin. Oncol. 40, 1301–1311 (2022).
Cheng, Y. et al. Benmelstobart with anlotinib plus chemotherapy as first-line remedy for ES-SCLC: a randomized, double-blind, part III trial. J. Thorac. Oncol. 18, S44 (2023).
Ohe, Y. et al. BEAT-SC: a randomized part III examine of bevacizumab or placebo together with atezolizumab and platinum-based chemotherapy in sufferers with extensive-stage small cell lung most cancers (ES-SCLC) [abstract]. J. Clin. Oncol. 42 (Suppl. 16), 8001 (2024).
Sen, T. et al. Mixture remedy of the oral CHK1 inhibitor, SRA737, and low-dose gemcitabine enhances the impact of programmed dying ligand 1 blockade by modulating the immune microenvironment in SCLC. J. Thorac. Oncol. 14, 2152–2163 (2019).
Sen, T. et al. Focusing on AXL and mTOR pathway overcomes main and purchased resistance to WEE1 inhibition in small-cell lung most cancers. Clin. Most cancers Res. 23, 6239–6253 (2017).
Sen, T. et al. Focusing on DNA harm restore in small cell lung most cancers and the biomarker panorama. Transl. Lung Most cancers Res. 7, 50–68 (2018).
Taniguchi, H. et al. Focused therapies and biomarkers in small cell lung most cancers. Entrance. Oncol. 10, 741 (2020).
Taniguchi, H. et al. WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. Cell Rep. 39, 110814 (2022).
Sen, T. et al. Focusing on DNA harm response promotes antitumor immunity by means of sting-mediated T-cell activation in small cell lung most cancers. Most cancers Discov. 9, 646–661 (2019).
Jones, R. et al. A part I/II trial of oral SRA737 (a Chk1 Inhibitor) given together with low-dose gemcitabine in sufferers with superior most cancers. Clin. Most cancers Res. 29, 331–340 (2023).
Qu, T., Li, B. & Wang, Y. Focusing on CD47/SIRPα as a therapeutic technique, the place we’re and the place we’re headed. Biomark. Res. 10, 20 (2022).
Tomita, Y. et al. In small cell lung most cancers sufferers handled with RRx-001, a downregulator of CD47, decreased expression of PD-L1 on circulating tumor cells considerably correlates with medical profit. Transl. Lung Most cancers Res. 10, 274–278 (2021).
Yamada, T. et al. Genetically engineered humanized anti-ganglioside GM2 antibody in opposition to a number of organ metastasis produced by GM2-expressing small-cell lung most cancers cells. Most cancers Sci. 102, 2157–2163 (2011).
Taniguchi, H. et al. Position of CD38 in anti-tumor immunity of small cell lung most cancers. Entrance. Immunol. 15, 1348982 (2024).
Rudin, C. M. et al. Scientific profit from immunotherapy in sufferers with SCLC is related to tumor capability for antigen presentation. J. Thorac. Oncol. 18, 1222–1232 (2023).
Dowlati, A. et al. Immune checkpoint blockade final result in small-cell lung most cancers and its relationship with retinoblastoma mutation standing and performance. JCO Summary. Oncol. 6, e2200257 (2022).
Wollenzien, H., Afeworki Tecleab, Y., Szczepaniak-Sloane, R., Restaino, A. & Kareta, M. S. Single-cell evolutionary evaluation reveals drivers of plasticity and mediators of chemoresistance in small cell lung most cancers. Mol. Most cancers Res. 21, 892–907 (2023).
Tian, Y. et al. Single-cell transcriptomic profiling reveals the tumor heterogeneity of small-cell lung most cancers. Sign. Transduct. Goal. Ther. 7, 346 (2022).
Stewart, C. A. et al. Single-cell analyses reveal elevated intratumoral heterogeneity after the onset of remedy resistance in small-cell lung most cancers. Nat. Most cancers 1, 423–436 (2020).
Dowlati, A. et al. Scientific correlation of extensive-stage small-cell lung most cancers genomics. Ann. Oncol. 27, 642–647 (2016).
Wildey, G. et al. Retinoblastoma expression and concentrating on by CDK4/6 inhibitors in small cell lung most cancers. Mol. Most cancers Ther. 22, 264–273 (2023).
Coleman, N., Zhang, B., Byers, L. A. & Yap, T. A. The position of Schlafen 11 (SLFN11) as a predictive biomarker for concentrating on the DNA harm response. Br. J. Most cancers 124, 857–859 (2021).
Zoppoli, G. et al. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes most cancers cells to DNA-damaging brokers. Proc. Natl Acad. Sci. USA 109, 15030–15035 (2012).
Lok, B. H. et al. PARP inhibitor exercise correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung most cancers. Clin. Most cancers Res. 23, 523–535 (2017).
Abdel Karim, N. F. et al. SWOG S1929: part II randomized examine of upkeep atezolizumab (A) versus atezolizumab + talazoparib (AT) in sufferers with SLFN11 optimistic intensive stage small cell lung most cancers (ES-SCLC) [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 8504 (2023).
Ali, G. et al. Prevalence of delta-like protein 3 in a consecutive collection of surgically resected lung neuroendocrine neoplasms. Entrance. Oncol. 11, 729765 (2021).
Wermke, M. et al. First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in sufferers (pts) with DLL3-positive (DLL3+) small-cell lung most cancers (SCLC) and neuroendocrine carcinoma (NEC) [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 8502 (2023).
Johnson, M. L. et al. Interim outcomes of an ongoing part 1/2a examine of HPN328, a tri-specific, half-life prolonged, DLL3-targeting, T-cell engager, in sufferers with small cell lung most cancers and different neuroendocrine cancers [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 8566 (2022).
Wiedemeyer, W. R. et al. ABBV-011, a novel, calicheamicin-based antibody-drug conjugate, targets SEZ6 to eradicate small cell lung most cancers tumors. Mol. Most cancers Ther. 21, 986–998 (2022).
Morgensztern, D. et al. First-in-human examine of ABBV-011, a seizure-related homolog protein 6 (SEZ6)–concentrating on antibody-drug conjugate, in sufferers with small cell lung most cancers [abstract]. J. Clin. Oncol. 41 (Suppl. 16), 3002 (2023).
Lehman, J. M. et al. Somatostatin receptor 2 signaling promotes progress and tumor survival in small-cell lung most cancers. Int. J. Most cancers 144, 1104–1114 (2019).
Dowlati, A. et al. Sacituzumab govitecan (SG) as second-line (2L) remedy for intensive stage small cell lung most cancers (ES-SCLC): preliminary outcomes from the part II TROPiCS-03 basket trial [abstract 1990MO]. Ann. Oncol. 34 (Suppl. 2), S1061–S1062 (2023).
Johnson, M. et al. Ifinatamab deruxtecan (I-DXd; DS-7300) in sufferers with refractory SCLC: a subgroup evaluation of a part 1/2 examine. J. Thorac. Oncol. 18, S34–S55 (2023).
Hou, J. M. et al. Circulating tumor cells, enumeration and past. Cancers 2, 1236–1250 (2010).
Hou, J. M. et al. Scientific significance and molecular traits of circulating tumor cells and circulating tumor microemboli in sufferers with small-cell lung most cancers. J. Clin. Oncol. 30, 525–532 (2012).
Byers, L. A. & Rudin, C. M. Small cell lung most cancers: the place will we go from right here? Most cancers 121, 664–672 (2015).
Hodgkinson, C. L. et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung most cancers. Nat. Med. 20, 897–903 (2014).
Pizzutilo, E. G. et al. Liquid biopsy for small cell lung most cancers both de novo or reworked: systematic evaluate of various functions and meta-analysis. Cancers 13, 2265 (2021).
De Luca, A. et al. Promising position of circulating tumor cells within the administration of SCLC. Cancers 13, 2029 (2021).
Mohan, S. et al. Profiling of circulating free DNA utilizing focused and genome-wide sequencing in sufferers with SCLC. J. Thorac. Oncol. 15, 216–230 (2020).
Devarakonda, S. et al. Circulating tumor DNA profiling in small-cell lung most cancers identifies doubtlessly targetable alterations. Clin. Most cancers Res. 25, 6119–6126 (2019).
Nong, J. et al. Writer correction: Circulating tumor DNA evaluation depicts subclonal structure and genomic evolution of small cell lung most cancers. Nat. Commun. 10, 552 (2019).
Kilgour, E., Rothwell, D. G., Brady, G. & Dive, C. Liquid biopsy-based biomarkers of remedy response and resistance. Most cancers Cell 37, 485–495 (2020).
Almodovar, Okay. et al. Longitudinal cell-free DNA evaluation in sufferers with small cell lung most cancers reveals dynamic insights into remedy efficacy and illness relapse. J. Thorac. Oncol. 13, 112–123 (2018).
Church, M., Carter, L. & Blackhall, F. Liquid biopsy in small cell lung most cancers – a path to improved medical care? Cells 9, 2586 (2020).
Chemi, F. et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat. Most cancers 3, 1260–1270 (2022).
Tivey, A., Church, M., Rothwell, D., Dive, C. & Prepare dinner, N. Circulating tumour DNA – trying past the blood. Nat. Rev. Clin. Oncol. 19, 600–612 (2022).
Tong, L. et al. Tumor-derived DNA from pleural effusion supernatant as a promising different to tumor tissue in genomic profiling of superior lung most cancers. Theranostics 9, 5532–5541 (2019).
Jaiswal, S. et al. Age-related clonal hematopoiesis related to adversarial outcomes. N. Engl. J. Med. 371, 2488–2498 (2014).
Mondelo-Macía, P. et al. Present standing and future views of liquid biopsy in small cell lung most cancers. Biomedicines 9, 48 (2021).
Nong, J. et al. Circulating tumor DNA evaluation depicts subclonal structure and genomic evolution of small cell lung most cancers. Nat. Commun. 9, 3114 (2018).
Iacobuzio-Donahue, C. A. et al. Most cancers biology as revealed by the analysis post-mortem. Nat. Rev. Most cancers 19, 686–697 (2019).
Megyesfalvi, Z. et al. Unfolding the secrets and techniques of small cell lung most cancers development: novel approaches and insights by means of speedy autopsies. Most cancers Cell 41, 1535–1540 (2023).
Jereczek, B. et al. Post-mortem findings in small cell lung most cancers. Neoplasma 43, 133–137 (1996).
Thomas, A. et al. Durvalumab together with olaparib in sufferers with relapsed SCLC: outcomes from a part II examine. J. Thorac. Oncol. 14, 1447–1457 (2019).
Drapkin, B. J. et al. Genomic and practical constancy of small cell lung most cancers patient-derived xenografts. Most cancers Discov. 8, 600–615 (2018).
Lababede, O. & Meziane, M. A. The eighth version of TNM staging of lung most cancers: reference chart and diagrams. Oncologist 23, 844–848 (2018).
